Atlas Trials

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Clinical trial NCT04877821 · COMPLETED

Trial details

NCT number
NCT04877821
Sponsor
Guangdong Provincial People's Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2021-09-15
Primary completion
2023-08-31
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.